At the forefront of Amgen's growth strategy is its obesity program, headlined by MariTide. This potential blockbuster drug has garnered significant attention from analysts and investors alike.

Weight-loss drugs aren’t just slimming waists; they create a $100 billion market opportunity. With plenty up for grabs, ...

(Bloomberg) -- Amgen Inc.’s disclosed that US regulators paused the study of an early-stage obesity drug, a lucrative market the company is trying to crack. The Thousand Oaks, California-based ...

Glucagon-like peptite-1 (GLP-1) receptor agonists, such as Wegovy and Ozempic, have taken the food industry by storm. With ...

At the forefront of Amgen's growth strategy is its obesity program, headlined by MariTide. This potential blockbuster drug has garnered significant attention from analysts and investors alike. Cantor ...

Hello, everyone, and how are you today? We are doing just fine, thank you, especially since the middle of the week is upon us. After all, we have made it this far, so we are determined to hang on ...

Large American pharmaceutical companies are showing a distinct trend never seen before: they are increasingly looking for ...